Previous research has demonstrated that blocking the PD-1/PD-L1 pathway can rejuvenate the cytotoxic potential of T cells and elicit tumor regression, thus establishing PD-1 and PD-L1 as promising therapeutic targets 104,105. Here, CD274 is linked to neoplasm.